AKT1 and endometrial cancer: In endometrial cancer, gain-of-function mutations promote tumor progression through EGFR/PI3K/AKT signaling and EMT, leading to metastasis, treatment resistance, and chromosomal instability that triggers cGAS-STING pathway and immune evasion [17].